3Guevara M, Gines P, Femrdez EG, et al. Reversibility of hepatorenal syndrome by prolonged administration of omipressin and plasma volume expansion. Hepatology, 1998, 27 ( 1 ) : 35 -41.
4Moreau R, Durand F, Poynard T, et al. Terlipression in patient with cirrhosis and type I hepatorenal syndrome A Retrospective muhicenter study. Gastroenterology, 2002, 122:923-930.
5Ortega R, Gines P, Uiiz J, et al. Tedipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrszldomized study . Hepalology, 2002, 36(4): 941- 948.
6Dumortier J, Lepretre J , Scalone O, et al. Successful treatment of hepatic hydrothorax with octreotide. Eur J Gastroenterol Hepatol, 2000, 12(7): 817 -820.
7Demirtas S, Bozbas A , Akbay A, et al. Diagnostic value of serum cystatin C for evaluation of hepatorenal syndrome. Clin Chim Acta, 2001, 311 (2): 81-89.
8Duvoux C, Zanditenas D, Hezode C, et al. Effects of noradrenalin and al- bumin in patients with type I hepatorenal syndrome: a pilot study, 2002, 36 : 374-380.
9Fevery J, Van Cutsem E, Nevens F, et al. Reversal of hepatorenal syndrome in four patients by perora/ misoprostol (prostag/andin E1 analogue) and albumin administration . J Hepatol, 1990, 11(2): 153 -158.
10Gines A, Salmeron JM, Gines P, et al. Oral misoprostol or intravenous prostaglandin E2 do not improve renal function in patients With cirrhosis and ascites with hyponatremia or renalfailure. J Hepatol, 1993, 17(2): 220 - 226.
